SCHEMBL29773000

SCHEMBL29773000

O=C(O)[C@H](Cc1c[nH]c2ccccc12)NCc1c[nH]c2ccccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.65
ACE P12821 3/20 0.64
SMN1; SMN2 Q16637 1/20 0.63
KDM4E B2RXH2 3/20 0.62
MAPT P10636 2/20 0.62
APAF1 O14727 1/20 0.62
POLB P06746 1/20 0.62
RECQL P46063 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
MEN1 O00255 1/20 0.62
LMNA P02545 1/20 0.62
MPO P05164 1/20 0.62
TSHR P16473 1/20 0.62
BLM P54132 1/20 0.62
PMP22 Q01453 1/20 0.62
KMT2A Q03164 1/20 0.62
HIF1A Q16665 1/20 0.62
ITGB2 P05107 3/20 0.61
ICAM1 P05362 3/20 0.61
ITGAL P20701 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL150050 1.00 ALOX15 (0.65) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL22654181 1.00 ALOX15 (0.65) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL9583736 0.92 KCNT1 (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL900917 0.92 KCNT1 (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL29810269 0.92 KCNT1 (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL8705016 0.92 KCNT1 (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL9115505 0.89 ALOX15 (0.65) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL8710928 0.89 SMN1; SMN2 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL9115508 0.89 ALOX15 (0.65) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL8710933 0.89 SMN1; SMN2 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US claimed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO claimed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP claimed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN claimed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US claimed
WO-2022204327-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2022-09-29 WO claimed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP claimed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN claimed
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES VICTORIA LINK LIMITED (NZ) 2024-08-29 US disclosed
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
EP-4351581-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES Victoria Link Limited (NZ) 2024-04-17 EP disclosed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO disclosed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP disclosed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN disclosed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US disclosed
WO-2022260535-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES VICTORIA LINK LIMITED (NZ) 2022-12-15 WO disclosed
WO-2022204327-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2022-09-29 WO disclosed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP disclosed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES EBNA1BP2, RPL35, RPL7 ALOX15 3707/4885ACE 610/4885SMN1; SMN2 2626/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB ALOX15 2364/4885ACE 4693/4885SMN1; SMN2 4084/4885
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCB, PRKCI ALOX15 725/4885ACE 4672/4885SMN1; SMN2 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.